BioSpace News Archive

Business

Alkermes plc Reports Second Quarter 2023 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2023.

July 26, 2023
·
18 min read
Drug Development

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

Alterity Therapeutics today announced that an independent Data Monitoring Committee (DMC) recommended the ATH434-201 Phase 2 study continue as planned.

July 26, 2023
·
6 min read
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Healthcare Limited is pleased to announce that it has completed a constructive pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S. Food and Drug Administration (‘FDA’) for its proprietary drug product IHL-675A for treatment of rheumatoid arthritis (‘RA’).

July 26, 2023
·
7 min read
Business

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

Monte Rosa Therapeutics, Inc. today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.

July 26, 2023
·
4 min read
Business

Metastatic breast cancer’s Trojan horse

Lymph nodes are one of the body’s first lines of defense against disease. Immune cells are dispatched from these biological police stations to fight off intruders. But somehow, lymph nodes are also the first stop for most metastatic cancers.

July 26, 2023
·
2 min read
Business

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023Conference call scheduled for 8:00 a.m. Eastern Time

Ardelyx, Inc. today announced it will hold a conference call on Wednesday, August 2, 2023, at 8:00 a.m. Eastern Time to discuss second quarter financial results and provide a business update.

July 26, 2023
·
1 min read
Drug Development

Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical Research

Recce Pharmaceuticals Ltd is pleased to announce it dosed both male and female subjects in a Phase I/II urinary tract infection (UTI) clinical trial evaluating R327 at faster infusion rates at Scientia Clinical Research.

July 26, 2023
·
2 min read
Business

Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

Alpha Teknova, Inc. today announced that the Company will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, following the close of market.

July 26, 2023
·
1 min read
Business

Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023.

July 26, 2023
·
1 min read
Drug Development

Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder

Oryzon Genomics, S.A. today reports that full patient recruitment has been completed in its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder.

July 26, 2023
·
8 min read